Press releases
- 4basebio Plc - 4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program
- 4basebio Plc - 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine
- 4basebio Plc - 4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of Excellence
- 4basebio Plc - Holding(s) in Company
- 4basebio Plc - Exercise of Options
- 4basebio Plc - Directors' Dealings
- 4basebio Plc - Long-Term Incentive Plan and Exercise of Options
More ▼
Key statistics
As of last trade 4Basebio PLC (88Q:BER) traded at 12.40, -0.80% below its 52-week high of 12.50, set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.00 |
---|---|
High | 12.40 |
Low | 11.90 |
Bid | 11.60 |
Offer | 13.30 |
Previous close | 12.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 12.81m |
Free float | 3.89m |
P/E (TTM) | -- |
Market cap | 133.81m GBP |
EPS (TTM) | -0.5094 GBP |
Data delayed at least 15 minutes, as of Apr 23 2024 13:10 BST.
More ▼